Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 FY2025 Earnings Call Transcript

Ono Pharmaceutical Co., Ltd. (OTCPK:OPHLF) Q1 FY2025 Earnings Conference Call August 1, 2025 1:00 AM ET

Company Participants

Hirokazu Kitada – Corporate Participant
Sales and Marketing – Corporate Participant
Hiroyuki Takahashi – Director of Oncology Business Division, Sales and Marketing
Masaki Ito – Corporate Executive Officer & Div. Director of Corporate Strategy & Planning, Bus. Management Div.
Ryuta Imura – Senior Director, Corporate Communications
Tatsuya Okamoto – Corporate Officer & Executive Director, Clinical Development, Oncology Clinical Development Div.

Conference Call Participants

Yamaguchi – Unidentified Company
Citigroup – Unidentified Company
Hashiguchi – Unidentified Company
Daiwa Securities – Unidentified Company
Muraoka – Unidentified Company
Morgan Stanley MUFG Securities – Unidentified Company
Sakai – Unidentified Company
UBS Securities – Unidentified Company
Ueda – Unidentified Company
Goldman Sachs – Unidentified Company
Wada – Unidentified Company
SMBC Nikko Securities – Unidentified Company
Wakao – Unidentified Company
JPMorgan Securities – Unidentified Company

Ryuta Imura

Thank you very much for attending ONO PHARMACEUTICAL CO., LTD.’s Financial Results Meeting for Q1 of the fiscal year ending March 2026 today.

I am Imura from Corporate Communications, and I will be your moderator.

As the time has come, we will hold the briefing in online format from now on.

First, I would like to introduce the attendees from the Company:

Itoh, Corporate Executive Officer and Division Director, Corporate Strategy and Planning, Business Management Division; Okamoto, Corporate Officer, Executive Director, Clinical Development; Kitada, Corporate Officer, Executive Director, Sales and Marketing; and Takahashi, Director of Oncology Business Division.

Here are some of the details for today.

First, Itoh, Division Director of Corporate Strategy and Planning, Business Management Division, will give an overview of financial results for Q1 of the fiscal year ending March 31, 2026, followed by an update on the progress of development products by Okamoto, Executive Director of Clinical Development; and finally, Kitada of Sales and Marketing will give